AOD 9604 is a synthetic peptide made from a small fragment of human growth hormone. Specifically, it copies amino acids 177 through 191 of the growth hormone molecule, the section responsible for breaking down fat. It was developed as an anti-obesity drug with the idea that isolating this fat-burning fragment would deliver weight loss benefits without the side effects of full growth hormone therapy. While it showed early promise and has a strong safety record, its development as a pharmaceutical was abandoned in 2007 after it failed to produce meaningful weight loss in a large clinical trial.
How AOD 9604 Works
Human growth hormone is a large protein with many functions: it builds muscle, strengthens bones, regulates blood sugar, and breaks down stored fat. AOD 9604 is a 16-amino-acid chain (sequence: YLRIVQCRSVEGSCGF) that mimics only the fat-burning portion of that larger molecule. It selectively activates the process of lipolysis, which is the breakdown of fat stored in fat cells, while leaving other growth hormone functions untouched.
This selectivity was the whole point. Full growth hormone therapy raises levels of a secondary hormone called IGF-1, which can cause insulin resistance, joint swelling, and other problems with long-term use. Because AOD 9604 is just a small fragment, it doesn’t trigger those downstream hormonal effects. In clinical studies, it produced none of the adverse effects associated with full-length growth hormone treatment, and it did not alter blood sugar regulation or IGF-1 levels.
What the Clinical Trials Found
AOD 9604 went through six formal clinical studies in humans, progressing from early safety testing through larger efficacy trials. In a 12-week randomized trial, subjects taking 1 mg per day lost an average of 2.6 kg (about 5.7 pounds), compared to 0.8 kg (1.8 pounds) in the placebo group. That difference, while statistically real, was modest.
The decisive moment came in 2007, when a larger 24-week trial enrolled 536 subjects at various doses (0.25 mg, 0.5 mg, and 1 mg daily). The peptide failed to produce significant weight loss compared to placebo over that longer period. The drug’s developer terminated the obesity program after those results. No further large-scale human trials for fat loss have been published since.
This is the central tension with AOD 9604: it reliably triggers fat breakdown in lab settings and animal models, but that mechanism hasn’t translated into clinically meaningful weight loss in humans. The gap between “activates lipolysis” and “makes people noticeably thinner” turned out to be too wide.
Safety Profile
If the efficacy data was disappointing, the safety data was remarkably clean. Across all six human studies, with doses ranging from 25 micrograms per kilogram of body weight (injected intravenously) up to 54 mg per day (taken orally), AOD 9604 displayed a safety and tolerability profile indistinguishable from placebo. No participant withdrew due to a side effect related to the peptide. No serious adverse events were linked to it. Blood tests showed no anti-AOD 9604 antibodies in any patient tested, meaning the immune system didn’t react against it.
This safety record is the main reason AOD 9604 remains in circulation despite its failed obesity trials. It received Generally Recognized as Safe (GRAS) status in the United States as a dietary supplement ingredient, which allows it to be sold outside the pharmaceutical approval pathway.
Joint and Cartilage Research
More recently, researchers have explored AOD 9604 for a completely different purpose: joint repair. In a 2015 study using rabbits with artificially induced knee osteoarthritis, weekly injections of AOD 9604 directly into the joint enhanced cartilage regeneration compared to saline. When combined with hyaluronic acid (a lubricant already used in joint injections), the results were even better. The combination group had significantly less cartilage damage and recovered from limping faster than animals receiving either treatment alone.
This is still animal research, and rabbit knees are not human knees. But the findings have fueled interest in AOD 9604 as a joint therapy, and some clinics now offer it as an intra-articular injection for osteoarthritis. No large human trials have confirmed whether these cartilage benefits hold up in people.
Regulatory and Athletic Status
AOD 9604 occupies an unusual regulatory space. It holds GRAS status in the U.S. as a dietary supplement ingredient, meaning the FDA has not objected to its use in food and supplement products at notified levels. However, it is not FDA-approved as a drug for any condition. It has no approved medical indication for weight loss, joint repair, or anything else.
For athletes, the rules are unambiguous. The World Anti-Doping Agency (WADA) classifies AOD 9604 as a prohibited substance under Section S2 of its banned list, which covers peptide hormones, growth factors, and related substances. It falls specifically under growth hormone analogues and fragments. The ban applies at all times, both in and out of competition. Any athlete subject to WADA testing who uses AOD 9604 risks a doping violation regardless of whether it actually enhances performance.
What Doses Were Studied
The clinical trials tested a wide range of doses across both injectable and oral forms. Intravenous doses ranged from 25 to 400 micrograms per kilogram of body weight in early safety studies. Oral capsules and tablets were tested at daily doses from 0.25 mg up to 54 mg. The 12-week trial that showed a small weight loss effect used 1 mg per day orally, while the failed 24-week trial tested 0.25, 0.5, and 1 mg daily tablets.
Outside of clinical trials, AOD 9604 is commonly sold as a subcutaneous injection (typically around 300 micrograms per dose) by compounding pharmacies and peptide suppliers. These protocols are not based on successful human efficacy data. They draw loosely from the clinical trial dosing but are administered by a different route than what was formally studied. If you’re considering AOD 9604 through a clinic or provider, it’s worth knowing that the evidence base for any specific protocol is thin.
The Bottom Line on Effectiveness
AOD 9604 is a well-tolerated peptide with a clear biological mechanism: it mimics the fat-burning segment of growth hormone without triggering growth hormone’s broader hormonal effects. Its safety profile across multiple human trials is genuinely impressive. But safety and effectiveness are different questions, and on effectiveness, the human data for fat loss is weak. The largest and longest trial found no benefit over placebo. The joint repair research is intriguing but limited to animal models. What you’re left with is a peptide that does something real at the cellular level but hasn’t proven it does something meaningful at the scale of a whole person.